Who
Fletcher Payne
Other role
Company insider
Files Form 4 as: Sr VP and CFO, Aptose Biosciences; Chief Financial Officer, Gyre Therapeutics.
In numbers
- Trades disclosed
- 33
- Buys
- 2
- Sells
- 0
- Bought
- $27K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 20 Aug 2015
- Last trade
- 30 Jun 2026
- Last filed
- 1 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 1 Jul 2026 | Aptose BiosciencesBiotechnology | SEC FORM 4 Code D | $382222 at $1.72 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose BiosciencesBiotechnology | SEC FORM 4 Code D | $3822 at $1.72 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —55,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —55,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —200,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code D | —1,000,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —200,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,000,000 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciences | SEC FORM 4 Code D | $382222 at $1.72 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Aptose Biosciences | SEC FORM 4 Code D | $3822 at $1.72 | filing |
| 5 Feb 2024filed 7 Feb 2024 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 19 Jan 2023filed 23 Jan 2023 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 19 Jan 2023filed 23 Jan 2023 | Aptose Biosciences | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 19 Sep 2022filed 21 Sep 2022 | Aptose Biosciences | SEC FORM 4 Bought | $6,80010,000 at $0.68 | filing |
| 27 Jun 2022filed 28 Jun 2022 | Aptose Biosciencesoption or derivative | SEC FORM 4 Code A | —1,000,000 at $0.00 | filing |
| 12 Aug 2019filed 12 Aug 2019 | GYRE Gyre TherapeuticsBiotechnology | SEC FORM 4 Code A | $7,6821,180 at $6.51 | filing |
| 11 Feb 2019filed 13 Feb 2019 | GYRE Gyre TherapeuticsBiotechnology | SEC FORM 4 Code A | $7,0541,002 at $7.04 | filing |
| 4 Feb 2019filed 4 Feb 2019 | GYRE Gyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,503 at $0.00 | filing |
| 4 Feb 2019filed 4 Feb 2019 | GYRE Gyre TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,9591,503 at $4.63 | filing |
| 24 Jan 2019filed 28 Jan 2019 | GYRE Gyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
News
Gyre Therapeutics (NASDAQ:GYRE) vs. GSK (NYSE:GSK) Head-To-Head ContrastGYRE · dailypolitical.com · 19 Oct 2026GSK (NYSE:GSK) versus Gyre Therapeutics (NASDAQ:GYRE) Financial ContrastGYRE · themarketsdaily.com · 15 Oct 2026Contrasting Scienture (NASDAQ:SCNX) & Gyre Therapeutics (NASDAQ:GYRE)GYRE · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Fletcher Payne; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.